Effects of gm1 ganglioside in cerebrovascular diseases: A double-blind trial in 40 cases

Leontino Battistin, Augusta Cesari, Francesco Galligioni, Gino Marin, Marino Massarotti, Daniela Paccagnella, Andrea Pellegrini, Gianfranco Testa, Paolo Tonin

Research output: Contribution to journalArticlepeer-review


A randomized, double-blind trial on the effects of GM1 ganglioside in cerebrovascular diseases was done on 40 patients; the treatment (40 mg/day i.m. injection) began after the acute phase and lasted 6 weeks. 18 cases took the drug and 16 the placebo. The evaluation of the cases was made by graduating the severity of the clinical signs, and some neurophysiological and morphological parameters, i.e., EEGs, flash-evoked potentials and computer tomography scans. We found that the drug, in comparison with the placebo treatment, improved the clinical signs and also the neurophysiological parameters, whereas it was ineffective for the morphological damage. These data seem of some interest in relation to the action of GM1 ganglioside in the processes of neurotransmission and neuronal plasticity as described in the experimental animal.

Original languageEnglish
Pages (from-to)343-351
Number of pages9
JournalEuropean Neurology
Issue number5
Publication statusPublished - 1985


  • Cerebrovascular diseases
  • GM<inf>1</inf> ganglioside
  • Neuronal plasticity
  • Neurotransmission phenomena

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Effects of gm1 ganglioside in cerebrovascular diseases: A double-blind trial in 40 cases'. Together they form a unique fingerprint.

Cite this